anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a study in pre-menopausal and perimenopausal women with onset of rheumatoid arthritis (RA) of less than 10 years duration, to be conducted at the Clinical Center of National Institutes of Health and The General Clinical Research Center of the Johns Hopkins Bayview Medical Center, Baltimore, MD. This investigation will explore the possible impact of systemically released inflammatory cytokines on suppression of the GH/IGF-1 axis, and the relationships of altered endocrine-immune function with body composition, endocrine, metabolic and vascular functions thought to be associated with RA-related sarcopenia, osteopenia and increased cardiovascular risk. In phase I of the study, we shall admit RA patients and control subjects to the Clinical Center for a 26-36 hour period for assessments of the GH/IGF-I axis, cytokines, body composition, endocrine-metabolic and cardiovascular functions, and quality of life. We plan to initiate Phase I of the study to compare baseline endocrine and inflammatory parameters in RA patients to matched normal controls. Phase II of the study, we shall enroll a new group of RA patients to evaluate the above outcome measures at baseline and after six months of treatment with standard therapy, using the soluble p75 TNF receptor molecule etanercept, that has recently been approved by the FDA for the treatment of patients with early RA. Phase 2 of this study will be initiated upon access to etanercept and completion of Phase I of the study.
(1) The abstract shall merely serve the purpose of technical information; in particular, it shall not be taken into account for the purpose of interpreting the scope of protection. (2) The abstract shall be so drafted that it can efficiently serve as a scanning tool for purposes of searching in the particular art. (3) The abstract shall consist of the following: (i) a summary of the disclosure as contained in the description, the claims, and any drawings, indicating the technical field to which the invention pertains and drafted in a way which allows the clear understanding of the technical problem, the gist of the solution of that problem through the invention and the principal use of uses of the invention; and (ii) Where applicable, the chemical formula which, among all the formulae contained in the application, best characterises the invention. (4) The abstract shall be as concise as the disclosure permits (preferably 50 to 150 words). (5) The abstract shall not contain statements on the alleged merits or value of the invention or on its speculative application. (6) Each main technical feature mentioned in the abstract and illustrated by a drawing in the application shall be followed by a reference sign, placed between parentheses.
Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a NY-ESO-1 antigen. Included are recombinant T cell receptors (TCRs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including CD4+ T cells, CD8+ T cells, natural killer T cells, γδ T cells, and progenitor cells, such as haematopoietic stem cells. The modified cells are capable of direct recognition of a cancer cell expressing a NY-ESO-1 antigen by human leukocyte antigen (HLA) class II-restricted binding of the TCR to the NY-ESO-1 antigen expressed by the cancer cell without presentation of the antigen by antigen presenting cells. In embodiments, the NY-ESO-1 antigen is displayed by the tumor cells. Also included is a method for prophylaxis and/or therapy of cancer by administering modified cells that express a recombinant TCR. Methods for making expression vectors and/or cells which express a recombinant TCR and identifying TCRs to make the expression vectors are also included.
BACKGROUND AND PURPOSE: Flat-panel detector CT immediately after mechanical thrombectomy can detect complications, including early hemorrhagic transformation and subarachnoid hyperdensities. The clinical significance of subarachnoid hyperdensities in patients undergoing mechanical thrombectomy remains unclear.
MATERIALS AND METHODS: We studied 223 patients who underwent mechanical thrombectomy for anterior circulation stroke who had flat-panel detector CT performed immediately after the procedure and had follow-up imaging within 24 hours. Subarachnoid hyperdensity severity was categorized into 5 grades (subarachnoid hyperdensities, 0: absent to subarachnoid hyperdensities, IV: extensive). Baseline and procedural characteristics as well as outcome measures were analyzed using group comparisons and multivariable logistic regression analyses.
RESULTS: Overall, 100/223 (45%) patients showed subarachnoid hyperdensities on immediate postinterventional flat-panel detector CT. The factors associated with an increased subarachnoid hyperdensity risk were the following: medium-vessel occlusion or distal-vessel occlusion compared with a large-vessel occlusion, a more distal device position, a higher number of device passes, a larger volume of contrast applied, worse final reperfusion expanded TICI, and after receiving IV thrombolysis. The occurrence of subarachnoid hyperdensity grades II-IV was independently associated with worse functional outcomes (adjusted OR for mRS, 3-6: 2.2; 95% CI 1.1-4.3), whereas patients with subarachnoid hyperdensity grade I had outcomes similar to those in patients without subarachnoid hyperdensities.
CONCLUSIONS: Our study identified risk factors for subarachnoid hyperdensities, most of which reflect increasingly challenging procedures or more peripheral recanalization attempts. The presence of subarachnoid hyperdensity grades II-IV was associated with poorer outcomes, suggesting the need for personalized strategies to reduce its incidence and severity or potentially improve recovery after subarachnoid hyperdensities.
249,093. Deutsche Goldund Silber- Scheideanstalt vorm. Roessler, (Assignees of Rath, C., and Binz, A.). March 10, 1925, [Convention date]. Void [Published under Sect. 91 of the Acts]. Immunizing and like serums; bacteria, cultivating.-Cancerous or like tissue is treated with degradation or dissolving agents, such as ferments, so as to liberate the contained causative micro-organisms, from which cultures and immunizing and like serums or other preparations may be obtained in the usual manner. In an example, a cancerous tumour is comminuted and treated with trypsin solution at blood heat for 1 ¢ hours. The resulting preparation is spread on a nutrient medium such as agar and incubated for several days. The culture so obtained is purified by selection so as to obtain spore-forming rod-shaped organisms of defined staining characteristics. In place of trypsin the tumour may be treated with other ferments or enzymes such as pepsin, and erepsin, or with solvents for lipoids, or by hydrolysis with acids or alkalies, or with a succession of such agents. Pure cultures of the organisms may be obtained by aerobic or anaerobic methods, Curative serums may be obtained by injecting an animal first with cultures which have been killed and then with cultures of gradually increasing virulence, or killed or non-virulent cultures may be used for direct injection into the diseased organism.
Patients with locally advanced rectal cancer who undergo neoadjuvant chemoradiotherapy may achieve pathological complete response (pCR). The incidence of recurrence is low among patients with pCR, there is still a lack of consensus on postoperative treatment and follow-up strategy. This review summarizes the recurrence patterns of patients with pCR, including distant metastasis rate, characteristics of distant metastasis time and location, local recurrence rate, and local recurrence time. The aim is to provide reference for the postoperative treatment and follow-up strategy of patients with pCR. Patients with pCR have a low recurrence rate, with infrequent local recurrence. Distant metastasis is the most common recurrence pattern, primarily in the lung and secondly in the regional lymph node. The time of recurrence is delayed which suggests the need for appropriate adjustments to follow-up strategy, extending the follow-up period, and placing emphasis on monitoring sites prone to recurrence.
Pacemakers are widely used in cardiotomy patients, while it's common that the patients happen to be pacemaker dependent. When the doctor decides to set the heart rate of the pacemaker, we record the hemodynamic parameters and peripheral perfusion index from 70-80-90-100-110 bpm.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular to dentistry, and can be applied for treatment of "dry socket", which is formed after complicated tooth extraction. Method includes filling socket with blood clot. Clot is formed by intake from patient's vein of blood in quantity 15-25 ml with following centrifugation at rate 10-12 thousand turn/min for 5-7 minutes and addition in it after that of hydroxiapole - "ôÉ-45" and 0.5 g of metrogyl. After introduction of blood clot into socket, from above additionally applied is membrane "TahoComb" in such a way, that it totally closes socket edges and is tightly fixed to clot and gum edges. ^ EFFECT: method makes it possible to reduce treatment terms and maximally reduce development of complication in treatment of said category of patients without carrying out additional medical manipulations. ^ 2 ex
Cardiac fibrosis, a crucial pathological characteristic of various cardiac diseases, presents a significant treatment challenge. It involves the deposition of the extracellular matrix (ECM) and is influenced by genetic and epigenetic factors. Prior investigations have predominantly centered on delineating the substantial influence of epigenetic and epitranscriptomic mechanisms in driving the progression of fibrosis. Recent studies have illuminated additional avenues for modulating the progression of fibrosis, offering potential solutions to the challenging issues surrounding fibrosis treatment. In the context of cardiac fibrosis, an intricate interplay exists between m6A epitranscriptomic and epigenetics. This interplay governs various pathophysiological processes: mitochondrial dysfunction, mitochondrial fission, oxidative stress, autophagy, apoptosis, pyroptosis, ferroptosis, cell fate switching, and cell differentiation, all of which affect the advancement of cardiac fibrosis. In this comprehensive review, we meticulously analyze pertinent studies, emphasizing the interplay between m6A epitranscriptomics and partial epigenetics (including histone modifications and noncoding RNA), aiming to provide novel insights for cardiac fibrosis treatment.
Thirty years ago a Norwegian publication explored what athletes with eating disorders have experienced as the causes to their condition. Early specialization and sports cultures with early introduction to weighing and weight adjustment, high training volume, and traumatic experiences (body comments, loss of an important coach, family events) were highlighted as key self-perceived causes. This study and findings have been regularly cited and upheld as facts in professional and research literature but have not been further explored or replicated and confirmed since. This may be part of the reason why the sports world has not fully recognized its responsibility for measures despite the prevalence of eating disorders remaining unchanged over these decades. There is a need to continue exploring why some athletes develop eating disorders while others from the same conditions do not. This can be done by building on previous research and knowledge, examining specific personal or situational factors that may constitute an additional vulnerability, and also by considering self-experiences. There is also a need to understand what athletes believe can help reduce body dissatisfaction and eating disorders. This is especially relevant when considering how both the sports world and society have changed over these 30 years. Early specialization in sports, the desire to be a talent at a young age, and the massive influence of social media are factors that may be particularly challenging risk factors. Better knowledge can be used to develop supportive guidelines for sports teams and cultures, necessary rule changes, and in the education, training, and awareness of sports coaches and support staff. Such knowledge is also crucial when the sports world itself is to design the content of a national action plan to prevent body dissatisfaction and eating disorders in sports.
Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg. Participants will be switched to another oral therapy as per Investigator's discretion.
An N-substituted phenyl-2-pyridone endoperoxide and application thereof, belonging to the technical field of organic compound synthesis and medicine. The invention discloses that the internal peroxy compound can be converted into N-substituted phenyl-2-pyridone at a certain temperature, and simultaneously release singlet oxygen and triplet oxygen. The series of endoperoxides have excellent anti-pulmonary fibrosis effect and can obviously inhibit inflammatory factors, and the effect is obviously superior to that of pirfenidone which is a medicine on the market. The anti-lung cancer experimental results show that the series of compounds not only can inhibit proliferation and migration of cancer cells at the cell level, but also can inhibit growth of tumors at the living body level. The safety evaluation result shows that the series of endoperoxides have better safety, and have no obvious injury to other organs when treating pulmonary fibrosis, lung cancer and lung fibrosis combined lung cancer. The endoperoxides integrate a plurality of therapeutic factors and are expected to be developed into first-line medicaments for treating pulmonary fibrosis, lung cancer and lung fibrosis combined lung cancer.
A benign solvent for dissolving proteins comprises alcohol, salt and water. The ratio by volume of water to alcohol is between about ninety-nine -to-one and about one-to-ninety-nine. A salt concentration is between near zero moles per liter and the maximum salt concentration soluble in water. The amount of protein by weight as compared to the mixture of water and alcohol is between near zero percent and about 25 percent. A method for forming a protein structure from a benign solvent comprises forming a benign solvent from water, alcohol, and salt; and dissolving a protein in the benign solvent to form a protein solution. The method further comprises extracting the protein from the protein solution; and arranging the protein into a protein structure.
AIM: This study aimed to evaluate the preclinical safety of Shenfu injection for the treatment of sepsis. Tests were designed and conducted to determine the acute and long-term toxicity of Shenfu injection in rats, based on the recommended indications and dosage for human use.
MATERIALS AND METHODS: Rats were administered 22.5 g of raw drug/kg/day via tail vein injection. Toxicity symptoms were monitored for 14 days following the intravenous injection of Shenfu injection, and target organs affected by toxicity were analyzed. To assess long-term toxicity, rats were given 12, 9, or 6 g of raw drug/kg/day by intraperitoneal injection, equivalent to 12, 9, and 6 times the daily clinical dose for adult sepsis patients (3.3 mL of stock solution per 1 g of raw drug/kg/day), for 30 consecutive days. This was followed by a 28-day recovery period after withdrawal of the drug. During the administration and recovery periods, signs of toxicity were observed and compared with those in the control (stromal fluid) group. The aim was to predict potential clinical adverse reactions, including the nature and severity of these reactions, dose-response and time-response relationships, and the reversibility of the effects. Additionally, the study sought to identify the target organs or tissues potentially affected by repeated administration and suggest clinical indicators that should be monitored during the product's use. Furthermore, the safety of co-administration with commonly used chemical medications for the treatment of sepsis was investigated.
RESULTS: In the acute toxicity test, administration of the maximum dose of Shenfu injection (75 mL of stock solution/22.5 g of raw drug/kg/day) via tail vein injection resulted in transient symptoms, including piloerection (vertical hair response), weight loss, and reduced food intake. In the long-term toxicity experiments, rats received intraperitoneal injections of 0.3 g/mL (stock solution), 0.225 g/mL, and 0.15 g/mL Shenfu injection per day, which corresponded to 12, 9, and 6 times the daily clinical dose for adults with sepsis. The injections were administered twice daily for 30 days, followed by a 28-day drug withdrawal period for recovery. After 28 days, no significant toxicological changes were observed, apart from a hemodilution effect caused by the excessive volume of the drug and a slight increase in alkaline phosphatase and total bilirubin levels. The effects were reversible upon drug discontinuation.
CONCLUSIONS: A single intravenous injection of 22.5 g of raw drug/kg/day and long-term intraperitoneal administration of up to 12 g of raw drug/kg/day are considered safe doses for rats.
BACKGROUND: Cholinesterase is a classical nutritional and inflammatory marker. The aim of the present study was to evaluate the value of cholinesterase as a predictive marker for postoperative skeletal muscle loss after gastrectomy for gastric cancer.
METHODS: The study comprised 68 patients who had undergone gastrectomy for gastric cancer. Skeletal muscle mass was evaluated using skeletal mass index, and major skeletal muscle loss was defined as less than or equal to the median change rate (1-year postoperative/preoperative) of skeletal mass index in all patients. We explored the relationship between postoperative major skeletal muscle loss and disease-free survival and overall survival. Then we investigated the relationship between change rate of skeletal muscle index and serum cholinesterase levels after gastrectomy.
RESULTS: The median value of change rate of skeletal mass index was 0.93. Postoperative major skeletal muscle loss was significantly associated with disease-free survival after gastrectomy (P = 0.003). Although major skeletal muscle loss had worse overall survival, it was not significant (P = 0.058). The change rate of skeletal mass index and cholinesterase had a stronger positive correlation compared with other nutritional indices according to Spearman's rank correlation coefficient (r = 0.438, P ≤ 0.001).
CONCLUSION: Evaluation of serum cholinesterase levels may be valuable for predicting postoperative skeletal muscle loss after gastrectomy, suggesting the importance of cholinesterase in postoperative nutritional management of patients with gastric cancer.
This is a Phase 3, open-label, roll-over study to demonstrate the continued hepatic and non-hepatic safety and renal efficacy of lixivaptan in participants with ADPKD who previously experienced abnormal liver chemistry test results while treated with tolvaptan that resulted in permanent discontinuation of tolvaptan for that reason, and subsequently completed study PA-ADPKD-303, the open-label lead-in study with lixivaptan.

Assessments completed during the final 4 visits of PA-ADPKD-303, the lead-in study, will serve as the screening and baseline assessments for this roll-over study. Evaluation of eligibility will be completed at Visit 1 of this study, following signing of informed consent. Participants satisfying all study entry criteria at Visit 1 will be considered enrolled following completion of all Visit 1 study procedures and will be dispensed lixivaptan treatment to start the Lixivaptan Re-titration Period (1 to 2 weeks). During the Lixivaptan Re-titration Period, participants will have their dose of lixivaptan re-established based on the dose they were receiving at the completion of the lead-in study. Participants will continue on lixivaptan treatment for up to 104 weeks during the Maintenance Treatment Period and will be assessed at a study visit every 12 weeks. In between the quarterly study visits, participants will be required to have blood drawn for liver chemistry determinations every 4 weeks. At the end of 104 weeks, lixivaptan treatment will be stopped, and participants will enter a 4-week Follow-up Period during which final assessments of safety and efficacy will be obtained over 3 visits during a 28-day period.
PURPOSE: To determine whether the embryonic euploidy rate and live birth outcomes following single, euploid embryo transfer (SEET) differ among women of self-reported racial and ethnic backgrounds.
METHODS: This retrospective cohort study included all infertile patients of different self-reported racial backgrounds who underwent In vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) and an autologous single euploid embryo transfer (SEET) from December 2015 to December 2019 at a single private and academic assisted reproduction technology center. Primary outcome measures included ploidy rates among different racial groups. Secondary outcomes included clinical pregnancy, clinical pregnancy loss, and live birth rates.
RESULTS: Five thousand five hundred sixty-two patients who underwent an IVF cycle with ICSI-PGT-A were included. A total of 24,491 blastocysts were analyzed. White participants had on average more euploid embryos and higher euploidy rates when compared to their counterparts (p ≤ 0.0001). However, after controlling for confounding factors, there was no association between race and the odds of having  a higher euploidy rate (aOR 1.31; 95% CI 0.63-2.17, p = 0.42). A total of 4949 patients underwent SEET. Pregnancy outcomes did not differ among patients of varying self-reported races.
CONCLUSIONS: Euploidy rates and pregnancy outcomes were comparable among patients of different racial backgrounds who underwent a SEET.
A novel molded article exhibiting a gradual disintegration effect is prepared with pullulan. The effect is imparted by incorporating heteromannan into a pullulan molded article in an amount not exceeding the weight of the pullulan used. Galactomannans (e.g. guar gum, tara gum, and locust bean gum) and glucomannans (e.g. konjak mannan) are feasible as the heteromannan. The molded article is advantageously usable for industrial materials, pharmaceuticals, consumers' products, etc.
This study consisted of 2 phases. In Phase 1, participants wore contact lenses pre-soaked overnight in contact lens solution for 2 hours and 4 hours, separate days. A minimum of 7 days separated the wear periods. Ocular surface cells were collected after both wear periods. In Phase 2, participants wore their habitual contact lenses on a daily wear basis for 4 weeks with habitual lens care. Ocular surface cells were collected after Day 1 and Day 28. Phase 2 included eligible participants who completed Phase 1 and new participants. A participant was considered to be asymptomatic if he/she can typically wear contact lenses comfortably for at least 10 hours/day a minimum of 5 days/week, and symptomatic if he/she typically wears contact lenses for a minimum of 3 days/week and experiences ocular discomfort after less than 6 hours of wear. Phase 1 participants not eligible to participate in Phase 2 or uninterested in continuing into Phase 2 were exited from the study.